Today, on March 8th, the subscription period prior to listing of the Swedish femtech company Pharmiva begins.
Pharmiva focuses on medical innovations in women’s health. The company develops and markets patented medical products, and is committed to finding solutions against the increasing global threat of antimicrobial resistance to antibiotics.
Treatment of bacterial vaginosis
The company’s first product, Vernivia, is about to be launched as a treatment of bacterial vaginosis. Bacterial vaginosis is a type of vaginal inflammation caused by the overgrowth of bacteria naturally found in the vagina, which upsets the natural balance. Women in their reproductive years are most likely to get bacterial vaginosis, but it can affect women of any age. Vernivia is a prescription free vaginal mousse based on a patented drug delivery technology Venerol.
The global launch of Venivia will begin in Sweden and thereafter the treatment will be launched in Europe, the US and other markets, states the company. The goal is to become a global femtech company with a broad portfolio within vaginal health.
A Swedish competitor
Swedish company Gedea Biotech has developed a vaginal tablet, pHyph, that has been shown to have medical effect. When the company’s ongoing clinical study is finished, the company plans to launch the product. Gedea’s ambition is to develop the first antibiotic-free treatment that both prevents and treats bacterial vaginosis.
In Gedea’s ongoing study, three clinics in Sweden have been added to the previous four UK based clinics.
The period to subscribe ends on March 19th and the offer accounts for up to SEK 35 million.
“I am delighted to see such a great interest in our company and that more people recognize the large unexploited potential there is in investing in products that improves women’s health. The medical needs are enormous and our medtech products can improve vaginal health globally,” says Christina Östberg Lloyd, CEO, Pharmiva.
Photo of Christina Östberg Lloyd: Pharmiva